… head and neck cancer, a low dose of weekly paclitaxel has … efficacy and toxicity of weekly
paclitaxel alone in these patients. … weekly paclitaxel in patients with advanced head and neck …

… This study demonstrates that weekly paclitaxel has promising activity with acceptable … of
weekly paclitaxel in the treatment of recurrent or metastatic HNC, albeit that weekly paclitaxel …

… of cetuximab to weekly paclitaxel has demonstrated high efficacy in the first-line treatment
of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M-…

… The combination of weekly paclitaxel and cetuximab could be such an option; there have …
However, no comparisons of the weekly paclitaxel and cetuximab combination and the …

… ) in the three-weekly arm was 36% versus 52% in the weekly arm. Conclusion: Data from
our small study suggest that weekly paclitaxel plus platinum neoadjuvant chemotherapy may …

… In conclusion, our trial demonstrates that cetuximab plus weekly paclitaxel is active as first-line …
plus weekly paclitaxel may be an appropriate choice for poor performance status patients. …

… of paclitaxel may predict response to weekly paclitaxel in patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck. … Advanced head and neck cancers …

… report on weekly administration of carboplatin and paclitaxel, … rates, and toxic effects of weekly
paclitaxel and carboplatin in … or recurrent squamous cell carcinoma of the head and neck. …

… for recurrent/metastatic head and neck cancer when … weekly Paclitaxel plus Cetuximab as
second line of palliative chemotherapy. Patients with squamous carcinoma of head and neck …

… weekly paclitaxel versus cisplatin with concurrent radiation in locally advanced head and
neck … The rationale for using low dose weekly paclitaxel is based on preclinical and clinical …